Randomized Phase II Trial Of Interventional Therapy Investigate Cardiac Protection of Dexrazoxane In Women With Breast Cancer Having Experienced Grade 1 Cardiotoxicity During Prior Anthracycline-based Chemotherapy.
Patients with breast cancer receiving anthracycline chemotherapy randomized to 3
groups:chemotherapy plus low dose dexrazoxane,chemotherapy plus middle dose dexrazoxane,
chemotherapy only.Every patient receive at least 2 cycles anthracycline chemotherapy.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Occurence of cardiac toxicity in patients with breast cancer receiving anthracycline chemotherapy
xichun Hu, MD
member of Fudan University
China: Food and Drug Administration